Distinguished in Hemolytic Anemia

Selma S. Unal

Mersin, TR 
Distinguished in Hemolytic Anemia
Mersin, TR 
OverviewLocationsClinical Research

Overview

Selma Unal practices in Mersin, Turkey. Ms. Unal is rated as a Distinguished expert by MediFind in the treatment of Hemolytic Anemia. Her top areas of expertise are Hemoglobinopathy, Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 46 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 33 articles and participated in 2 clinical trials in the study of Hemolytic Anemia.

Gender
Female

Locations

Mersin, Turkey
Other Locations
52983, Turkey
Ankara, Turkey

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
Enrollment Status: Terminated
Publish Date: December 11, 2024
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
View 1 Less Clinical Trial

46 Total Publications

Increased serum YKL-40 levels in children with sickle cell disease.
Increased serum YKL-40 levels in children with sickle cell disease.
Journal: The Turkish journal of pediatrics
Published: June 03, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Unal's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile